MIOS

Summary

MIOS (meiosis regulator for oocyte development, HGNC:21905) is a protein-coding gene on chromosome 7p21.3, encoding GATOR2 complex protein MIOS (Q9NXC5). As a component of the GATOR2 complex, functions as an activator of the amino acid-sensing branch of the mTORC1 signaling pathway. It is a selective cancer dependency (DepMap: 46.4% of cell lines).

Predicted to enable zinc ion binding activity. Involved in cellular response to amino acid starvation; positive regulation of TORC1 signaling; and protein-containing complex localization. Located in several cellular components, including cytosol; lysosomal membrane; and nucleoplasm. Part of GATOR2 complex.

Source: NCBI Gene 54468 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 132 total
• Cancer dependency (DepMap): dependent in 46.4% of screened cell lines
• MANE Select transcript: NM_019005

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21905
Approved symbol	MIOS
Name	meiosis regulator for oocyte development
Location	7p21.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20323, MIO, Sea4, Yulink
Ensembl gene	ENSG00000164654
Ensembl biotype	protein_coding
OMIM	615359
Entrez	54468

Gene structure

Transcript identifiers

Ensembl transcripts: 37 — 34 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000340080, ENST00000405785, ENST00000433056, ENST00000433635, ENST00000445169, ENST00000456533, ENST00000461907, ENST00000479694, ENST00000493227, ENST00000899856, ENST00000899857, ENST00000899858, ENST00000899859, ENST00000899860, ENST00000899861, ENST00000899862, ENST00000899863, ENST00000899864, ENST00000899865, ENST00000899866, ENST00000899867, ENST00000928619, ENST00000963942, ENST00000963943, ENST00000963944, ENST00000963945, ENST00000963946, ENST00000963947, ENST00000963948, ENST00000963949, ENST00000963950, ENST00000963951, ENST00000963952, ENST00000963953, ENST00000963954, ENST00000963955, ENST00000963956

RefSeq mRNA: 5 — MANE Select: NM_019005 NM_001370076, NM_001370077, NM_001370078, NM_001370080, NM_019005

CCDS: CCDS43554

Canonical transcript exons

ENST00000340080 — 13 exons

Exon	Start	End
ENSE00000671256	7574098	7574196
ENSE00001086352	7572436	7573769
ENSE00001277599	7606996	7608932
ENSE00001538140	7568026	7568123
ENSE00001538142	7567607	7567688
ENSE00001821094	7566884	7567072
ENSE00003496511	7605942	7606071
ENSE00003504992	7589405	7589563
ENSE00003524046	7585636	7585805
ENSE00003594810	7583118	7583372
ENSE00003614156	7588498	7588563
ENSE00003659588	7596257	7596461
ENSE00003661878	7594980	7595132

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 96.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.4414 / max 217.0966, expressed in 1788 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77197	7.6593	1695
77199	3.6790	1480
77198	2.0011	1186
77200	0.8949	578
204349	0.1860	37
77201	0.0212	3

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tongue squamous epithelium	UBERON:0006919	96.26	gold quality
gastrocnemius	UBERON:0001388	95.35	gold quality
sperm	CL:0000019	95.01	gold quality
muscle of leg	UBERON:0001383	94.63	gold quality
pancreatic ductal cell	CL:0002079	94.29	gold quality
tibialis anterior	UBERON:0001385	94.03	gold quality
endothelial cell	CL:0000115	93.97	gold quality
gingival epithelium	UBERON:0001949	93.91	gold quality
deltoid	UBERON:0001476	93.77	gold quality
squamous epithelium	UBERON:0006914	93.63	gold quality
muscle organ	UBERON:0001630	93.48	gold quality
esophagus squamous epithelium	UBERON:0006920	93.40	gold quality
male germ cell	CL:0000015	93.16	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	93.11	gold quality
cervix squamous epithelium	UBERON:0006922	92.54	gold quality
tongue	UBERON:0001723	92.52	gold quality
tonsil	UBERON:0002372	92.33	gold quality
gingiva	UBERON:0001828	92.21	gold quality
superior surface of tongue	UBERON:0007371	91.88	gold quality
epithelium of esophagus	UBERON:0001976	91.80	gold quality
hindlimb stylopod muscle	UBERON:0004252	91.76	gold quality
body of tongue	UBERON:0011876	91.71	gold quality
cortical plate	UBERON:0005343	91.27	gold quality
skeletal muscle tissue	UBERON:0001134	91.21	gold quality
pharyngeal mucosa	UBERON:0000355	91.07	gold quality
triceps brachii	UBERON:0001509	90.86	gold quality
body of pancreas	UBERON:0001150	90.83	gold quality
gluteal muscle	UBERON:0002000	90.80	gold quality
quadriceps femoris	UBERON:0001377	90.33	gold quality
vastus lateralis	UBERON:0001379	90.26	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting MIOS, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-7156-5P	99.64	68.81	1369
HSA-MIR-6126	99.62	68.09	996
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-4273	99.45	67.93	1206
HSA-MIR-4796-5P	99.34	70.06	810
HSA-MIR-593-3P	99.22	67.28	1327

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 46.4% of screened cell lines.

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mios	ENSDARG00000102587
mus_musculus	Mios	ENSMUSG00000042447
rattus_norvegicus	Mios	ENSRNOG00000007924
drosophila_melanogaster	mio	FBGN0031399
caenorhabditis_elegans		WBGENE00018193

Protein

Protein identifiers

GATOR2 complex protein MIOS — Q9NXC5 (reviewed: Q9NXC5)

Alternative names: Missing oocyte meiosis regulator homolog

All UniProt accessions (4): C9JAQ1, C9JTV2, C9JUE6, Q9NXC5

UniProt curated annotations — full annotation on UniProt →

Function. As a component of the GATOR2 complex, functions as an activator of the amino acid-sensing branch of the mTORC1 signaling pathway. The GATOR2 complex indirectly activates mTORC1 through the inhibition of the GATOR1 subcomplex. GATOR2 probably acts as an E3 ubiquitin-protein ligase toward GATOR1. In the presence of abundant amino acids, the GATOR2 complex mediates ubiquitination of the NPRL2 core component of the GATOR1 complex, leading to GATOR1 inactivation. In the absence of amino acids, GATOR2 is inhibited, activating the GATOR1 complex. Within the GATOR2 complex, MIOS is required to prevent autoubiquitination of WDR24, the catalytic subunit of the complex. The GATOR2 complex is required for brain myelination.

Subunit / interactions. Component of the GATOR2 subcomplex, composed of MIOS, SEC13, SEH1L, WDR24 and WDR59. The GATOR2 complex interacts with CASTOR1 and CASTOR2; the interaction is negatively regulated by arginine. CASTOR1 and CASTOR2 convey leucine availability via direct interaction with MIOS. The GATOR2 complex interacts with SESN1, SESN2 and SESN3; the interaction is negatively regulated by amino acids. Interacts with SAR1A and SAR1B; the interaction is direct, disrupted by leucine and mediates the interaction of SAR1A or SAR1B with the GATOR2 complex to negatively regulate the TORC1 signaling upon leucine deprivation.

Subcellular location. Lysosome membrane.

Activity regulation. The GATOR2 complex is negatively regulated by the upstream amino acid sensors CASTOR1 and SESN2, which sequester the GATOR2 complex in absence of amino acids. In the presence of abundant amino acids, GATOR2 is released from CASTOR1 and SESN2 and activated.

Similarity. Belongs to the WD repeat mio family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NXC5-1	1	yes
Q9NXC5-2	2

RefSeq proteins (5): NP_001357005, NP_001357006, NP_001357007, NP_001357009, NP_061878* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR031488	Zn_ribbon_mio	Domain
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR037593	MIOS/Sea4	Family
IPR049092	MIOS_a-sol	Domain

Pfam: PF17034, PF21719, PF21720

UniProt features (29 total): binding site 14, repeat 6, modified residue 2, splice variant 2, mutagenesis site 2, zinc finger region 2, chain 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
9LWF	ELECTRON MICROSCOPY	3.41
9OTI	ELECTRON MICROSCOPY	3.5
9LVK	ELECTRON MICROSCOPY	3.59
7UHY	ELECTRON MICROSCOPY	3.66
9LVJ	ELECTRON MICROSCOPY	3.82

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NXC5-F1	83.29	0.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (14): 740; 775; 778; 788; 827; 830; 830; 832; 835; 838; 849; 854 …

Post-translational modifications (2): 759, 766

Mutagenesis-validated functional residues (2):

Position	Phenotype
560	impaired assembly of the gator2 complex.
785–788	impaired amino-acid-mediated mtorc1 activation.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9639288	Amino acids regulate mTORC1
R-HSA-2262752	Cellular responses to stress
R-HSA-8953897	Cellular responses to stimuli
R-HSA-9711097	Cellular response to starvation

MSigDB gene sets: 134 (showing top): BROWNE_HCMV_INFECTION_30MIN_DN, MODULE_97, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOCC_VACUOLAR_MEMBRANE, GOBP_POSITIVE_REGULATION_OF_TOR_SIGNALING, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_GLIAL_CELL_DEVELOPMENT, MODULE_182, GOBP_NEUROGENESIS, ATGCAGT_MIR217, YY1_Q6, GGCNKCCATNK_UNKNOWN, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_NEURAL_PRECURSOR_CELL_PROLIFERATION, GOBP_CELLULAR_COMPONENT_ASSEMBLY_INVOLVED_IN_MORPHOGENESIS

GO Biological Process (8): protein-containing complex localization (GO:0031503), cellular response to nutrient levels (GO:0031669), central nervous system myelin formation (GO:0032289), cellular response to amino acid starvation (GO:0034198), oligodendrocyte differentiation (GO:0048709), oligodendrocyte progenitor proliferation (GO:0070444), negative regulation of TORC1 signaling (GO:1904262), positive regulation of TORC1 signaling (GO:1904263)

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (8): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), lysosomal membrane (GO:0005765), cytosol (GO:0005829), cell junction (GO:0030054), GATOR2 complex (GO:0061700), lysosome (GO:0005764), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cellular response to starvation	1
Cellular responses to stimuli	1
Cellular responses to stress	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
TORC1 signaling	2
regulation of TORC1 signaling	2
macromolecule localization	1
response to nutrient levels	1
cellular response to stimulus	1
central nervous system myelination	1
myelin assembly	1
cellular response to starvation	1
response to amino acid starvation	1
central nervous system development	1
glial cell differentiation	1
gliogenesis	1
neural precursor cell proliferation	1
negative regulation of TOR signaling	1
positive regulation of TOR signaling	1
transition metal ion binding	1
binding	1
cation binding	1
nuclear lumen	1
intracellular anatomical structure	1
lysosome	1
lytic vacuole membrane	1
cytoplasm	1
protein-containing complex	1
Seh1-associated complex	1
lytic vacuole	1

Protein interactions and networks

STRING

1124 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MIOS	WDR59	Q6PJI9	998
MIOS	WDR24	Q96S15	998
MIOS	SEH1L	Q96EE3	997
MIOS	SEC13	P55735	996
MIOS	NPRL3	Q12980	840
MIOS	NPRL2	Q8WTW4	827
MIOS	DEPDC5	O75140	809
MIOS	RRAGB	Q5VZM2	717
MIOS	RRAGA	Q7L523	688
MIOS	RRAGC	Q9HB90	668
MIOS	ITFG2	Q969R8	649
MIOS	KICS2	Q96MD2	649
MIOS	CASTOR1	Q8WTX7	640
MIOS	KPTN	Q9Y664	618
MIOS	CASTOR2	A6NHX0	617

IntAct

107 interactions, top by confidence:

A	B	Type	Score
WDR24	MIOS	psi-mi:“MI:0915”(physical association)	0.940
MIOS	WDR24	psi-mi:“MI:0915”(physical association)	0.940
WDR24	SESN2	psi-mi:“MI:0914”(association)	0.890
SESN2	WDR24	psi-mi:“MI:0914”(association)	0.890
RBBP5	KMT2D	psi-mi:“MI:0914”(association)	0.840
MIOS	SEC13	psi-mi:“MI:0914”(association)	0.790
CASTOR1	CASTOR1	psi-mi:“MI:0914”(association)	0.770
PFDN4	PFDN6	psi-mi:“MI:0914”(association)	0.730
CCT2	TXNDC9	psi-mi:“MI:0914”(association)	0.730
SESN2	MIOS	psi-mi:“MI:0915”(physical association)	0.710
CASTOR1	CASTOR2	psi-mi:“MI:0914”(association)	0.710
CASTOR1	MIOS	psi-mi:“MI:0915”(physical association)	0.710
WDR24	CASTOR1	psi-mi:“MI:0914”(association)	0.690
WDR24	WDR59	psi-mi:“MI:0914”(association)	0.680

BioGRID (134): MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), MIOS (Affinity Capture-MS), RRAGA (Affinity Capture-Western), RRAGC (Affinity Capture-Western), MIOS (Affinity Capture-Western), MIOS (Affinity Capture-MS), GATSL3 (Affinity Capture-Western)

ESM2 similar proteins: A0JN62, A2RT67, A4IFB6, E1C3P4, F1QEB7, F1R7R1, O35099, O43264, O54921, O94967, P48553, P51593, Q08CL8, Q08CZ0, Q0VEJ0, Q28G25, Q3TLI0, Q4R350, Q5F3K0, Q5R9R1, Q5RFM4, Q5XH48, Q5XIA4, Q5ZIW2, Q641K1, Q6DE97, Q6NU53, Q6VNB8, Q7TMY8, Q7TSG1, Q7Z6Z7, Q8BH15, Q8CGF6, Q8IWR0, Q8IY22, Q8IZQ1, Q8K1X1, Q8N960, Q8QFR2, Q95LL7

Diamond homologs: A4QNS7, Q5RCA2, Q5U5D4, Q802U2, Q8VE19, Q9NXC5, Q9VQ89, B2VZH2, P38164, Q09866, Q2GVT8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
MIOS	“form complex”	GATOR2	binding
MIOS	“form complex”	“CASTOR1-GATOR2 arginine binding complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 87 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Amino acids regulate mTORC1	10	34.5×	7e-11
Prefoldin mediated transfer of substrate to CCT/TriC	5	34.0×	6e-05
Cellular response to starvation	6	17.1×	2e-04
SUMOylation of DNA damage response and repair proteins	5	12.6×	4e-03
Cilium Assembly	5	9.4×	9e-03
Organelle biogenesis and maintenance	6	6.8×	9e-03
Cellular responses to stress	8	5.1×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of TORC1 signaling	10	40.5×	2e-11
cellular response to amino acid starvation	8	31.8×	3e-08
positive regulation of TORC1 signaling	6	22.2×	5e-05
protein folding	6	7.8×	8e-03
protein stabilization	7	5.8×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

132 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	105
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1783 predictions. Top by Δscore:

Variant	Effect	Δscore
7:7582747:A:G	donor_gain	1.0000
7:7596251:TTGTA:T	acceptor_loss	1.0000
7:7596252:TGTA:T	acceptor_loss	1.0000
7:7596253:GTAGG:G	acceptor_loss	1.0000
7:7596254:TA:T	acceptor_loss	1.0000
7:7605936:TCATA:T	acceptor_loss	1.0000
7:7605939:TA:T	acceptor_loss	1.0000
7:7605940:A:G	acceptor_loss	1.0000
7:7605941:G:GA	acceptor_loss	1.0000
7:7567068:CTCAG:C	donor_loss	0.9900
7:7567069:TCAG:T	donor_loss	0.9900
7:7567071:AGGT:A	donor_loss	0.9900
7:7567073:GTC:G	donor_loss	0.9900
7:7567604:AAG:A	acceptor_gain	0.9900
7:7568024:A:AG	acceptor_gain	0.9900
7:7568025:G:GG	acceptor_gain	0.9900
7:7568025:GTGCT:G	acceptor_gain	0.9900
7:7568098:G:GT	donor_gain	0.9900
7:7588597:T:G	donor_gain	0.9900
7:7594973:GTTTT:G	acceptor_loss	0.9900
7:7594974:TTTTA:T	acceptor_loss	0.9900
7:7594975:TTTA:T	acceptor_loss	0.9900
7:7594976:TTAG:T	acceptor_loss	0.9900
7:7594977:TA:T	acceptor_loss	0.9900
7:7594978:AG:A	acceptor_gain	0.9900
7:7594979:GG:G	acceptor_gain	0.9900
7:7595133:G:GG	donor_gain	0.9900
7:7595370:GT:G	donor_gain	0.9900
7:7596255:A:AG	acceptor_gain	0.9900
7:7596256:G:GG	acceptor_gain	0.9900

AlphaMissense

5758 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:7572711:C:A	A79E	1.000
7:7572714:T:A	V80D	1.000
7:7572716:G:A	G81R	1.000
7:7572716:G:C	G81R	1.000
7:7572717:G:A	G81E	1.000
7:7572728:G:C	G85R	1.000
7:7572728:G:T	G85C	1.000
7:7572729:G:A	G85D	1.000
7:7572729:G:T	G85V	1.000
7:7572735:T:A	V87D	1.000
7:7572798:T:C	F108S	1.000
7:7572816:G:C	R114P	1.000
7:7572821:T:C	C116R	1.000
7:7572822:G:A	C116Y	1.000
7:7572823:T:G	C116W	1.000
7:7572831:T:A	L119H	1.000
7:7572836:T:A	W121R	1.000
7:7572836:T:C	W121R	1.000
7:7572838:G:C	W121C	1.000
7:7572838:G:T	W121C	1.000
7:7572864:C:A	A130D	1.000
7:7572866:G:C	A131P	1.000
7:7572869:G:C	G132R	1.000
7:7572870:G:A	G132D	1.000
7:7572878:A:G	K135E	1.000
7:7572879:A:C	K135T	1.000
7:7572879:A:T	K135M	1.000
7:7572880:G:C	K135N	1.000
7:7572880:G:T	K135N	1.000
7:7572885:G:C	R137T	1.000

dbSNP variants (sampled 300 via entrez): RS1000000245 (7:7598731 G>A,C), RS1000005435 (7:7598567 C>A,G,T), RS1000100277 (7:7602826 A>G), RS1000250949 (7:7575789 C>G), RS1000300538 (7:7583880 TTAAAA>T), RS1000347055 (7:7581245 G>C,T), RS1000361219 (7:7587370 A>C), RS1000425577 (7:7579264 C>A,T), RS1000438272 (7:7598153 G>T), RS1000562929 (7:7576857 A>G), RS1000708800 (7:7582447 G>A), RS1000736245 (7:7589290 G>A), RS1000739877 (7:7582776 G>T), RS1000784593 (7:7605127 A>G), RS1000914816 (7:7594644 T>C)

Disease associations

OMIM: gene MIM:615359 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009391_1481	Metabolite levels	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010414	triacylglycerol 52:2 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	2
Valproic Acid	increases expression, decreases expression	2
GSK-J4	decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
cobaltous chloride	decreases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Vorinostat	increases expression	1
Demecolcine	decreases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	affects expression	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases expression	1
Selenium	decreases expression	1
Tretinoin	decreases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1X3	Abcam HeLa MIOS KO	Cancer cell line	Female
CVCL_SY40	HAP1 MIOS (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.